Capital Impact Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

Capital Impact Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-111,449	Closed	-$1.4M	–	139
2017 Q4	$1.4M	Hold	111,449	–	–	0.6%	78
2017 Q3	$1.47M	Buy	111,449 +46,056	+70%	+$634K	0.66%	57
2017 Q2	$1.03M	Sell	65,393 -25,051	-28%	-$364K	0.47%	117
2017 Q1	$1.29M	Buy	90,444 +65,793	+267%	+$900K	0.51%	108
2016 Q4	$316K	Hold	24,651	–	–	0.13%	210
2016 Q3	$328K	Hold	24,651	–	–	0.14%	212
2016 Q2	$270K	Hold	24,651	–	–	0.13%	212
2016 Q1	$226K	Hold	24,651	–	–	0.11%	216
2015 Q4	$239K	Hold	24,651	–	–	0.11%	246
2015 Q3	$215K	Hold	24,651	–	–	0.11%	236
2015 Q2	$249K	Hold	24,651	–	–	0.11%	247
2015 Q1	$330K	Buy	+24,651	New	+$323K	0.15%	231

Other funds holding IRWD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Capital Impact Advisors's IRWD Position: Q1 2018 in Review

Capital Impact Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2018, closing a stake of 111,449 shares — an estimated $1.4M sold.

Capital Impact Advisors first reported a position in IRWD in Q1 2015 and held it in 12 quarters. The position peaked at $1.47M in Q3 2017. 149 funds tracked by Wall St. Rank hold IRWD as of Q1 2018.

Capital Impact Advisors reported no remaining Ironwood Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Capital Impact Advisors sold 111,449 Ironwood Pharmaceuticals shares in Q1 2018, an estimated $1.4M.
Capital Impact Advisors first reported a position in Ironwood Pharmaceuticals in Q1 2015 and held it in 12 quarters.
Capital Impact Advisors's Ironwood Pharmaceuticals position peaked at $1.47M in Q3 2017.
149 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2018.

Based on Capital Impact Advisors's 13F filing for Q1 2018, filed 11 Apr 2018.